Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top

Journal of Mammary Gland Biology and Neoplasia

Issue 3/2004

Chromosomal Instability and Breast Cancer Pathogenesis (Guest Editors: Ashok R. Venkitaraman and Thea D. Tlsty)

Content (7 Articles)

Editorial Introduction

Preface: Chromosomal Instability and Breast Cancer Pathogenesis

Ashok R. Venkitaraman

The Genetic Epidemiology of Breast Cancer Genes

Deborah Thompson, Douglas Easton

BRCA1 and BRCA2 in Breast Cancer Predisposition and Recombination Control

Ralph Scully, Anyong Xie

ATM and Genome Maintenance: Defining Its Role in Breast Cancer Susceptibility

Kum Kum Khanna, Georgia Chenevix-Trench

Genetic and Epigenetic Changes in Mammary Epithelial Cells May Mimic Early Events in Carcinogenesis

Thea D. Tlsty, Yongping G. Crawford, Charles R. Holst, Colleen A. Fordyce, Jianmin Zhang, Kimberly McDermott, Krystyna Kozakiewicz, Mona L. Gauthier

Centrosome Amplification and the Origin of Chromosomal Instability in Breast Cancer

Jeffrey L. Salisbury, Antonino B. D'Assoro, Wilma L. Lingle

Telomere Shortening Occurs Early During Breast Tumorigenesis: A Cause of Chromosome Destabilization Underlying Malignant Transformation?

Alan K. Meeker, Pedram Argani

Apr 04
Issue: 2/2004
Embryonic Genes in Mammary Gland Development and Tumorigenesis
Oct 04
Issue: 4/2004

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits